JP2008512094A - アテローム性動脈硬化症を評価する方法 - Google Patents

アテローム性動脈硬化症を評価する方法 Download PDF

Info

Publication number
JP2008512094A
JP2008512094A JP2007530430A JP2007530430A JP2008512094A JP 2008512094 A JP2008512094 A JP 2008512094A JP 2007530430 A JP2007530430 A JP 2007530430A JP 2007530430 A JP2007530430 A JP 2007530430A JP 2008512094 A JP2008512094 A JP 2008512094A
Authority
JP
Japan
Prior art keywords
fos
dusp1
protein
mrna
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007530430A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008512094A5 (https=
Inventor
ポール エム． ホーング
ウィルマー ディー． パティーノ
オーマー ワイ． ミアン
ジュ−ジェオング カング
聖明 的場
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of JP2008512094A publication Critical patent/JP2008512094A/ja
Publication of JP2008512094A5 publication Critical patent/JP2008512094A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Vascular Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2007530430A 2004-09-03 2005-09-02 アテローム性動脈硬化症を評価する方法 Pending JP2008512094A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60703104P 2004-09-03 2004-09-03
US61827504P 2004-10-12 2004-10-12
PCT/US2005/031469 WO2006029052A2 (en) 2004-09-03 2005-09-02 Methods for assessing atherosclerosis

Publications (2)

Publication Number Publication Date
JP2008512094A true JP2008512094A (ja) 2008-04-24
JP2008512094A5 JP2008512094A5 (https=) 2008-09-04

Family

ID=36036914

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007530430A Pending JP2008512094A (ja) 2004-09-03 2005-09-02 アテローム性動脈硬化症を評価する方法

Country Status (6)

Country Link
US (1) US7998682B2 (https=)
EP (1) EP1791977A2 (https=)
JP (1) JP2008512094A (https=)
AU (1) AU2005282636B2 (https=)
CA (1) CA2577819A1 (https=)
WO (1) WO2006029052A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011232218A (ja) * 2010-04-28 2011-11-17 Hitachi Ltd 動脈硬化の評価法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010108092A2 (en) * 2009-03-19 2010-09-23 Phenotypeit, Inc. Medical health information system
US20190156923A1 (en) 2017-11-17 2019-05-23 LunaPBC Personal, omic, and phenotype data community aggregation platform
WO2020139379A1 (en) 2018-12-28 2020-07-02 LunaPBC Community data aggregation, completion, correction, and use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2228235B1 (es) * 2002-12-17 2006-05-16 Consejo Sup. Investig. Cientificas Procedimiento de identificacion de nor-1 y/o nur77 y/o nurr1 para el diagnostico y seguimiento de enfermedades cardiovasculares.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011232218A (ja) * 2010-04-28 2011-11-17 Hitachi Ltd 動脈硬化の評価法
US9175346B2 (en) 2010-04-28 2015-11-03 Hitachi, Ltd. Evaluation method for arteriosclerosis

Also Published As

Publication number Publication date
WO2006029052A2 (en) 2006-03-16
WO2006029052A3 (en) 2006-07-27
AU2005282636B2 (en) 2010-01-07
CA2577819A1 (en) 2006-03-16
US7998682B2 (en) 2011-08-16
US20070258902A1 (en) 2007-11-08
AU2005282636A1 (en) 2006-03-16
WO2006029052A8 (en) 2007-04-19
EP1791977A2 (en) 2007-06-06

Similar Documents

Publication Publication Date Title
Theocharidis et al. Single cell transcriptomic landscape of diabetic foot ulcers
Calcagno et al. The myeloid type I interferon response to myocardial infarction begins in bone marrow and is regulated by Nrf2-activated macrophages
CN107099581B (zh) 预测、诊断和治疗特发性肺纤维化的方法
JP5199322B2 (ja) 硬化をもたらす増殖性疾患の検出方法及びキット、硬化をもたらす増殖性疾患の予防及び／又は治療剤、ならびに硬化をもたらす増殖性疾患の予防及び／又は治療に有効な物質を同定する方法及びキット
Mirza et al. Obesity-associated vitamin D deficiency correlates with adipose tissue DNA hypomethylation, inflammation, and vascular dysfunction
JP2013503643A (ja) 関節リウマチの治療、診断及びモニターするための方法
EP1869213A4 (en) METHOD AND COMPOSITIONS FOR EVALUATING THE DURABILITY OF A PATH IN THE BODY OF A RECIPIENT OF FIXED ORGAN TRANSPLANTS
JP2021514479A (ja) 全身性慢性炎症加齢を測定する方法
Salem et al. Gene and protein expression of chemokine (CC-Motif) ligand 19 is upregulated in unstable carotid atherosclerotic plaques
Kennel et al. Longitudinal profiling of circulating miRNA during cardiac allograft rejection: a proof-of-concept study
EP3620537A2 (en) Method for diagnosis of unstable atherosclerotic plaques
US20060003338A1 (en) System and methods for the management and treatment of vascular graft disease
ES2324751B1 (es) Metodos y kits para diagnosticar y/o pronosticar el estado de tolerancia en el trasplante de higado.
Avouac et al. Insights into the pathogenesis of systemic sclerosis based on the gene expression profile of progenitor‐derived endothelial cells
US7998682B2 (en) Method for assessing atherosclerosis by measuring expression of FOS or DUSP1 in monocytes
JP2007522800A (ja) 内皮細胞の発現プロファイルを用いた組織炎症応答の評価方法
US20080045582A1 (en) ENA-78 Gene Polymorphisms and Protein Concentrations as Diagnostic and Prognostic Tools
WO2005082008A2 (en) Methods for diagnosing and treating bladder cancer
US20070184466A1 (en) Detection, generation and uses of atherosclerosis-protective endothelium
US20080166734A1 (en) Genes and methods of using the same for diagnosis and for targeting the therapy of cardiovascular disease
US20030068645A1 (en) Methods and materials for evaluating cardiovascular conditions
WO2006132983A2 (en) Differential expression of molecules associated with vascular disease risk
Song et al. Galectin-3: A potential biomarker in pulmonary arterial hypertension
Du et al. Sfrp5 protects acute myocardial infarction by inhibiting macrophage foam cell formation and apoptosis via modulation of macrophage polarization and p38-MAPK/JNK/NF-κB pathways
US20050233330A1 (en) Method for identifying myelodysplastic syndrome-specific genes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080530

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110302

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111019